Oxytocin-based therapies have been proposed, with studies indicating that low-dose intranasal oxytocin is safe for individuals with PWS and may lead to reductions in appetite drive, as well as improvements in socialization, anxiety, and repetitive behaviors [75]. Here, OXT is linked to Prader-Willi syndrome.